Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for patients [1][2]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - Standard Health specializes in orthopaedic care and has provided NHS services since 2012, with plans for nationwide expansion [10]. Partnership Details - The new centre in Poole, Dorset, will cater to both NHS and private patients, offering procedures such as rotator cuff repair and knee replacements, and is expected to open in 2025 [1][3]. - Standard Health plans to open an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Operational Model - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits including increased procedural efficiency and high patient satisfaction rates [3][6]. - In the US, ASCs account for over 50% of all outpatient surgical procedures, with more than 6,000 facilities currently operating [3]. Market Demand - There are over 850,000 individuals waiting for orthopaedic surgery in the UK, highlighting the need for independent providers to meet this demand [3]. - The partnership aims to address the long wait times for procedures in the UK, providing a sustainable model for care [4]. Expected Benefits - The ASC model is associated with a 92% patient satisfaction rate and can reduce costs of joint replacements by 40% compared to hospital-based surgeries [6]. - The collaboration is expected to enhance the quality of care for patients and provide value for NHS commissioners [4].

Core Viewpoint - Brainlab AG, a medical technology company, has announced plans for an IPO on the Frankfurt Stock Exchange, aiming to raise up to €200 million to fund growth initiatives and strengthen its balance sheet and sales team [1] Company Summary - Brainlab is headquartered in Munich and focuses on developing software that enhances the precision, data-driven approach, and minimally invasive nature of surgical and cancer treatments [1] - The company also provides tools to help hospitals plan and guide medical procedures [1] Financial Summary - The IPO is expected to include secondary shares, although the announcement did not specify the number of shares to be issued [1] - The raised capital will be allocated towards growth plans, reinforcing the company's financial position and expanding its sales capabilities [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 質子治療大模型正式發佈 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 本公司於腫瘤精準診療技術領域取得重要進展，本公司自主研發的質子治療垂直 領域大語言模型正式發佈，並成功部署於廣州泰和腫瘤醫院。自廣州泰和腫瘤醫 院質子治療開診以來，質子治療已完成多例高質量患者治療案例，展現出了治療 精準、療效顯著、副作用降低等突出優勢。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 中國北京，2025年5月27日 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事 ...

Core Viewpoint - The article emphasizes "unconventional" entrepreneurial thinking as a means to identify and seize opportunities for success, suggesting that mindset plays a crucial role in responding to impending changes [2]. Group 1: "We Can Do It" - Companies should focus on their core competencies and be open to exploring new opportunities beyond their traditional capabilities, as demonstrated by Brazilian entrepreneur Arnold Correia, who successfully ventured into satellite broadcasting despite lacking prior knowledge [3][4]. Group 2: "Problem-Oriented, Not Product-Oriented" - Entrepreneurs should prioritize solving problems rather than merely focusing on product innovation. Jonathan Thorne's development of a non-stick surgical tweezer illustrates the importance of addressing significant issues in specific medical fields rather than just enhancing existing products [5][6]. Group 3: "Focus on Specific Markets" - Identifying and addressing needs within niche markets can lead to substantial opportunities. Phil Knight and Bill Bowerman's creation of Nike stemmed from recognizing the unique requirements of long-distance runners, leading to the development of specialized running shoes [7]. Group 4: "Boldly Ask for Money" - For startups, securing cash flow is vital. Elon Musk's approach at Tesla, where he sold 100 Roadsters before production, exemplifies the effectiveness of pre-selling to generate capital for development [8][9]. Group 5: "Borrowing Resources" - Entrepreneurs can leverage existing resources to minimize initial investment. Tristram and Rebecca Mayhew's Go Ape company successfully partnered with the Forestry Commission to utilize their parks for adventure courses, demonstrating the potential of collaborative resource sharing [10].

Core Viewpoint - The article discusses the development of wearable near-infrared (NIR) upconversion contact lenses (UCL) that enable humans to perceive NIR images, expanding the visual spectrum beyond the visible light range [3][9]. Group 1: Research Development - A research team from multiple institutions developed UCL that possess suitable optical properties, hydrophilicity, flexibility, and biocompatibility, allowing for the perception of NIR spatial and temporal color images [3][5]. - The UCL achieved a high doping ratio (7-9%) of upconversion nanoparticles (UCNP) while maintaining over 90% transparency in the visible light spectrum, significantly outperforming previously reported materials [5][6]. Group 2: Functional Capabilities - Mice wearing UCL were able to perceive NIR light and distinguish different temporal frequencies and orientations of NIR information [6]. - Human volunteers wearing UCL could see a range of NIR light intensities and accurately identify time-encoded information [6][9]. Group 3: Technological Innovations - The research team developed a wearable eyeglass system integrated with UCL to enhance spatial resolution, allowing volunteers to recognize complex NIR patterns with clarity similar to visible light vision [6][9]. - The use of trichromatic UCNP in the UCL enables the conversion of three different NIR wavelengths into red, green, and blue visible light, facilitating the perception of multi-spectral NIR colors [7][9]. Group 4: Future Applications - This technology has potential applications in medical fields, information processing, and visual assistance technologies, and may offer new solutions for treating visual disorders such as color blindness [9][12]. - The research emphasizes the need for further optimization, including improving upconversion efficiency and achieving directional emission of light from the lenses [12].

Assertio Holdings (ASRT) Conference Summary Company Overview - Assertio Holdings is a specialty pharmaceuticals company with a market cap of approximately $70 million and shares trading at around 70¢ [2][4] - The company is focused on long-term growth and has a leadership team with extensive commercial experience in various therapeutic areas [5][6] Core Assets and Financial Performance - Assertio's core assets include Rovidone and SYMPAZAN, with Rovidone being a novel long-acting G-CSF approved in the last twenty years, targeting a market worth about $1 billion [8][9] - The company reported net sales of $26 million for the first quarter and maintains a positive adjusted EBITDA with a cash balance of nearly $90 million [9] - The financial outlook for the year includes projected net sales of $108 to $123 million and non-GAAP EBITDA of $10 to $20 million [10] Transformation and Growth Strategy - The company is in a transformation phase, simplifying its corporate structure and optimizing its asset portfolio, focusing on growth assets like Rovidone and SYMPAZAN [12][15] - Assertio aims to reduce legal exposure, which will allow for reinvestment into the business and positively impact EBITDA [13][14] - Business development is seen as a key enabler for future growth, with a focus on oncology, neurology, and rare diseases [14] Product Insights - Rovidone contributes over half of the total net sales and is expected to grow modestly this year, with plans to expand into the commercial segment by 2026 [19][21] - SYMPAZAN, an oral film formulation for Lennox Gastaut syndrome, is projected to grow to $13 million this year and has the potential to reach $25 million in the coming years [28] Competitive Landscape - The market for white blood cell stimulants is competitive, with Rovidone competing against biosimilars like Neulasta. Assertio is focused on managing average selling prices (ASP) smartly to sustain growth [23][24] Legal and Operational Improvements - Assertio has successfully reduced its litigation overhead, particularly related to opioid litigation, which has allowed for a cleaner balance sheet and operational focus [36][38] - The company has divested certain assets to streamline operations and eliminate legal distractions [38] Future Outlook - The CEO expressed optimism about the company's trajectory, aiming for significant growth and improved operational efficiency over the next year [41][42] - Assertio is positioned to explore mergers and acquisitions to enhance its portfolio, supported by a strong balance sheet with $40 million in convertible debt due in 2027 [34][35] Key Takeaways - Assertio is undergoing a transformation aimed at growth, with a focus on optimizing its asset portfolio and reducing legal distractions [12][15] - The company has a solid financial outlook and is strategically positioned to capitalize on growth opportunities in specialty pharmaceuticals [10][14] - Assertio's leadership is optimistic about future performance, with plans to enhance product offerings and expand market presence [41][42]

Group 1 - JD Health and BD Medical have launched a new service called "Caring for Bedridden Women's Health: Professional Care Delivered to Home," starting in Beijing [2][3] - The service combines instant retail of medical health products with at-home nursing services, providing a new solution for urinary management for bedridden female patients [2][3] - The target demographic includes women with urinary incontinence, limited mobility, and post-operative patients, addressing complications associated with catheter use [2] Group 2 - PureWick® is an innovative non-invasive urinary management solution designed specifically for bedridden women, improving comfort and dignity while simplifying the workflow for caregivers [3] - Users in Beijing can order PureWick® products through the JD app and receive at-home care services from experienced nurses, ensuring professional care and privacy [3] - This collaboration aims to contribute to the "Healthy China 2030" strategic goals by providing more efficient and user-centered home care solutions [4]

一句话趋势：机器人与半导体投资热度高涨，低空经济成科技与制造赛道热门。 过去一周披露的投融资案例显示，科技与制造依然是市场关注的重点，新资金持续向前沿技术集聚，涵 盖机器人、半导体、低空经济、先进制造等领域，呈现出资本对科技创新和产业升级的支持以及对未来 科技趋势的布局。 在已披露交易中： 21创投不完全统计，5月12日—5月18日，报告日期内国内一级市场发生融资事件37起。其中，有32笔融 资披露了融资金额和币种信息，总规模约合人民币42.65亿元。 01、机器人、半导体和医疗技术领域完成多笔融资 本周融资数量最多的行业领域仍是科技与制造。在三大行业领域的诸多赛道中，机器人赛道完成8笔融 资，融资金额超13.4亿元人民币；半导体赛道完成5笔融资，融资金额超7.75亿元人民币；医疗技术赛道 完成4笔融资，披露的融资金额超1亿元人民币。 02、北京市、广东省和上海市完成多笔融资 从披露获投企业的地域分布来看，本周的融资地区主要集中在北京市、广东省和上海市，分别完成8 笔、8笔、6笔融资。 03、哪些投资机构较为活跃 从机构投资活跃度来看，本周珠海科创投、中科创星、毅达资本、水木清华校友种子基金、深创投和临 港数 ...

Financial Performance - PAVmed's Q1 2025 revenue and management fee income was $3158 thousand, a decrease of $352 thousand compared to $3510 thousand in Q1 2024[23] - The company's operating expenses decreased significantly from $15046 thousand in Q1 2024 to $5454 thousand in Q1 2025, a reduction of $9592 thousand[23] - Net income for Q1 2025 was $18623 thousand, a substantial improvement of $37135 thousand compared to a loss of $18512 thousand in Q1 2024[23] - PAVmed reported an EBITDA of $19007 thousand in Q1 2025, compared to a negative EBITDA of $14813 thousand in Q1 2024, an increase of $33820 thousand[23] - Non-GAAP adjusted loss improved by $7705 thousand, from a loss of $8615 thousand in Q1 2024 to a loss of $910 thousand in Q1 2025[23] - Non-GAAP adjusted loss per share improved from $(099) in Q1 2024 to $(007) in Q1 2025, an increase of $092[23] Balance Sheet - PAVmed's cash position increased by $1515 thousand, from $1185 thousand in 4Q24 to $2700 thousand in 1Q25[22] - Equity method investments in Lucid increased by $21004 thousand, from $25637 thousand in 4Q24 to $46641 thousand in 1Q25[22] - Senior secured convertible notes decreased by $22500 thousand, from $29100 thousand in 4Q24 to $6600 thousand in 1Q25[22] - Preferred shares outstanding were 24480 thousand in 1Q25[22] - Shares outstanding increased from 112 million to 168 million, an increase of 56 million shares[22] Business Updates - Lucid Diagnostics' EsoGuard revenue for Q1 2025 was $08 million, with a test volume of 3034[17] - PAVmed strengthened its balance sheet by netting approximately $161 million in proceeds from an underwritten public offering of common stock[17]

报告撰写人、德国联邦外贸与投资署专家托马斯·博扬表示，中国继续位居德国投资主要来源国前列， 德国也是中国在欧洲投资布局的最大受益方。他指出，中企越来越聚焦可再生能源、电池供应链、汽 车、医疗技术、机器人等领域，尤其是这些行业的软件解决方案。博扬还说，除德国外，中企对外投资 活动在全球范围内同样保持强劲增长势头，尤其在新冠疫情结束后增幅显著。 中国德国商会本月早些时候发布报告称，尽管面对高额关税威胁，德企对华投资战略保持强劲。50%的 企业计划未来两年增加投资，另有超1/3的受访企业加速在华本土化以应对贸易紧张局势。德国 table.media网站3月报道称，2024年，德国企业在中国新投资了57亿欧元，与上一年相比增长了1/4。 【环球时报特约记者 文简】德国联邦外贸与投资署12日发布的《2024年外国企业在德投资报告》显 示，中国是德国第三大投资来源国，项目数量达199个。 报告显示，2024年，德国各州共登记1724个外国直接投资项目，包括绿地投资、扩建项目、迁移项目， 但不包括并购，同比小幅下降2%；外国企业在德投资金额仍保持在232亿欧元的高位，1/5的外企将德 国作为生产或研发基地。美国是德国最大的 ...